reports
Aptose Biosciences Inc: 1 director
A director at Aptose Biosciences Inc bought 17,000 shares at 3.140USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2...
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023 EHA Abstract on Tuspetinib and Venetoclax Recently Published SAN DIEGO and TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that the company management team will provide a clinical update on Saturday, June 10, 2023, at 12:00 PM EST / 6:00 PM CEST, in conjunction with EHA 2023 International Congress...
Aptose Enters into $25 Million Committed Equity Facility
Aptose Enters into $25 Million Committed Equity Facility SAN DIEGO and TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has entered into a common share purchase agreement and registration rights agreement with an institutional investor. The agreement governs a Committed Equity Facility that provides Aptose the right, in its sole option and discretion without obl...
Aptose Biosciences Announces Results of Annual and Special Meeting of ...
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders SAN DIEGO and TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that, at the Company’s annual and special meeting of shareholders held today, May 23, 2023 (the “Meeting”), the proposed reverse stock split (the “Reverse Stock Split”) of the Company’s common shares (the “Common Shares”), as de...
Aptose Reports Results for the First Quarter 2023
Aptose Reports Results for the First Quarter 2023 ─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for Relapsed/Refractory AML Patients in APTIVATE Expansion Trial ─ ─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial; Early Clinical Activity Already Noted ─ ─ Tuspetinib Superior Safety Profile Continues ─ ─ Luxeptinib G3 Formulation Continuous Dosing is On...
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Co...
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets 2023 Global Healthcare Conference on May 17, 2023. The Aptose management team also will be hosting one-on-one meet...
Aptose to Report First Quarter 2023 Financial Results and Hold Confere...
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023 SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:Monday, May 8, 2023Time:5:00 PM ETAudio Webcast Only:Q&A ...
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology...
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel at Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference on April 20, 2023. The Aptose management te...
Aptose Biosciences to Participate in Cantor’s The Future of Oncology V...
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company will be participating in Cantor Fitzgerald’s The Future of Oncology Virtual Symposium being held April 3-5, 2023, in a virtual format. The Cantor Healthcare Research team will be hosting a series of insightful fireside chats, panel...
Aptose Reports Results for the Fourth Quarter and Full Year 2022
Aptose Reports Results for the Fourth Quarter and Full Year 2022 ─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─ ─ Continuous Dosing of G3 Formulation of Luxeptinib Ongoing ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology compa...
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, is aware of reports related to Silicon Valley Bank (“SVB”) and questions raised by interested parties. Aptose has not entered into a line of credit with SVB, and therefore has no exposure related to any credit facility. Aptose held a deposit account at S...
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results a...
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023 SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, March 23, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date: Thursday, ...
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Co...
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference being held March 13-15, 2023, in a virtual format. Oppenheimer 33rd Annual Healthcare Conference Presentat...
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in P...
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia • AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial• New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient• Aptose Elucidates Rationale for Tuspetinib’s Superior Safety Profile SAN DIEGO and TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, ...
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate at the upcoming Biotech Showcase™ 2023 Conference on Tuesday, January 10th, 2023, at 10:00 a.m. PST in San Francisco, CA. Conference Presentation Details: Date: Tuesday, Janu...
Aptose Biosciences Establishes New At-The-Market Facility
Aptose Biosciences Establishes New At-The-Market Facility SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced it has entered into an equity distribution agreement (the “Equity Distribution Agreement”) with JonesTrading Institutional Services LLC, as agent (the “Agent”). Under the terms of the Equity Distribution Agreement, the Company may, from time to time, ...
Aptose Announces Updated Clinical Responses, Breadth of Activity, and ...
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to Become the Preferred Kinase Inhibitor for Triplet Combination, Maintenance Therapy, and Patients Failed by Prior FLT3 InhibitorsTuspetinib Enrolling APTIVATE Expansion Trial for Monotherapy and Combination TherapyLuxeptinib ...
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib ...
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th Data to be presented in poster at ASH Annual Meeting SAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company’s management team will provide a corporate update on Sunday, December 11, 2022, at 10:00 AM EST / 9:00 CST, in conjunction with poster present...
Aptose Treats First Patient with Continuous Dosing of New “G3” Formula...
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase 1a/b clinical trial in patients with relapsed or refractory (r/r) acute my...
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation SAN DIEGO and TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that clinical data for tuspetinib (formerly HM43239), a myeloid kinome inhibitor, and luxeptinib, a dual lymphoid and myeloid inhibitor, have been accepted for poster presentations at the 64th Am...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.